Oxford Nanopore Technolo... Share Discussion Threads

[minsky] 19/6/2024 12:34

So they've already expired?

[seball] 19/6/2024 12:04

Oxford Nanopore Technologies PLC's Limited Availability Tranche (LAT) shares are set to expire at the conclusion of the company's 2024 Annual General Meeting or by the close of business on September 12, 2024, whichever comes first​. .

[p1nkfish] 19/6/2024 11:44

Currently it could rally 20% and still not break the downtrend.

If the ultimate target is towards 300p+ then missing the first 20p to de-risk an entry won't be existential.

What's the rush until it's confirmed to have turned?

[takeiteasy] 19/6/2024 11:41

any possible triggers out there to stem the tide? I've been waiting a long time to find this bottom...

[seball] 19/6/2024 11:32

ok thanks Bamboo, have you a link?

[seball] 19/6/2024 10:02

Hi Bamboo, I have heard dates of August and October for the expiry of LAT shares. In any case this is very cheap at this price.

[minsky] 19/6/2024 07:50

As things stand just now ONT would be around position 276 of the FTSE 350.

[bamboo2] 19/6/2024 06:15

By my reckoning there are only two more trading days until the LAT shares expire.

Shorts can no longer rely on the fact that there is little chance of corporate activity.

We may eventually see ONT included in FTSE 100/250, and passive trackers, and funds that precluded anti-takeover co's could become buyers.

[bamboo2] 15/6/2024 08:22

Most of the presentations from LC2024 uploaded now, of particular interest are those from the Clinical Day. Gordon Sanghera suggested that commercial traction from clinical applications will begin in 2025, providing an alternative income stream for ONT.

===========================================

A prospective clinical pilot study was conducted in ICU patients with respiratory failure, using a unified respiratory metagenomic (RMg) workflow encompassing DNA and RNA sequencing.

Respiratory metagenomics in clinical service


PulseNet — the national molecular surveillance network of over 80 public health labs in the United States, connects food, water, and one-health related illnesses that may be part of an outbreak —fully implemented WGS in 2019. WGS data is comprehensive: antimicrobial resistance, virulence markers, serotype markers, plasmids, and core and accessory genes are all characterized as part of the WGS workflow. Additionally, sequence data is portable and is shared between United States federal agencies, over 80 PulseNet International member countries, and public repositories, including the National Center for Biotechnology Information (NCBI). Currently, PulseNet USA sequences approximately 65,000 Salmonella, Escherichia, Listeria, Vibrio, Campylobacter, and Shigella isolates annually.

Whole-genome sequencing in PulseNet foodborne molecular surveillance systems


Vid from recent Genomics England event.
Empowering comprehensive sequencing at scale [with Greg Elgar]

[p1nkfish] 14/6/2024 12:56

Better off waiting for confirmation on the turn, miss the first 15%?

[takeiteasy] 14/6/2024 07:25

Still can't seem to find any safe bottom to enter here - will have to be super patient indeed. American rival share price still rather sour - does not help sentiment... nai etc

[brucie5] 14/6/2024 07:11

Wise words.

[bones698] 13/6/2024 16:31

Unfortubtaley it looks like the. Next move might be downwards unless revenues and evidence and ebita pick up dramatically. In this sector with everyone struggling with funding and cutting back customers are likely to hold back which won't help ONT

Happy to watch for now and see how fast the cash is being spent. They need to either massively increase revenue or look to cut costs and keep that cash in these times

[brucie5] 12/6/2024 08:46

Take it easy, I've been out of these for a couple of weeks now as the share reconsolidates at the £ level. Worth watching or accumulating as I think the outer will come quickly one way or another.

[bamboo2] 10/6/2024 07:36

Uses Nanopore

================
Laura Foster BBC News, Thetford Forest

Scientists sampling DNA in the air to monitor the spread of deadly diseases said their work could help make food prices cheaper.

The Earlham Institute said its air sampler processes detect bacteria, viruses and other micro-organisms - which pose a threat to plants, animals and humans - more quickly and accurately than other techniques.

This could help farmers grow crops more cheaply and efficiently as they would not need to use as many chemicals.

It could also transform environmental conservation work as well as public health measures.



======================================

Much work going on in the rest of Europe on this topic.

"Environmental microbiome diversity and stability is a barrier to antimicrobial resistance gene accumulation"

[takeiteasy] 07/6/2024 04:27

The most significant detractors to performance in the period were Ocado, Alnylam and Oxford Nanopore.

Oxford Nanopore flagged that tepid academic research budget growth, alongside a curtailing of its UAE genome sequencing project, would act as a drag on 2024 revenue growth. These issues as unhelpful but transient. Ultimately, they distract from what we think is the compelling evidence building to support its novel technology in clinical and applied sequencing use-cases, previously off- limits to DNA sequencing from a cost or practicality perspective. The company has an increasing pool of industry partners and collaborators with whom it is looking to develop new applications eg Biomerieux in antimicrobial resistance, Lonza in quality testing of mRNA therapeutics and Guy's & Thomas' NHS Trust to investigate rapid identification and analysis of pathogens in intensive care units. In time, such opportunities could support a market opportunity far bigger for DNA analysis than that currently represented by the conventional academic-skewed research market.

BG EWI IT assessment of ONT as a top 10 holding in their financial reports yesterday.

They are being careful in their language - "could" rather than "will" etc...so plenty of uncertainty around great possibilities etc :) dyor etc

[takeiteasy] 07/6/2024 04:18

I do pop in every now and again here, waiting and waiting for a time to join in but even with these steep falls this market sector arguably with high interest rates not helping the cause is struggling across the board.

Will read the link above and see the firm's take on the future.

But we clearly have yet to find a proper support and downtrend pattern remains ongoing.

nai etc

[bamboo2] 04/6/2024 18:47

Oxford Nanopore’s Clive Brown Looks Back and Ahead June 4, 2024

[bamboo2] 03/6/2024 17:05

ONT at ESHG today, this is the agenda for discussion,



Such is the interest in ONT kit, it's standing room only again. This was the situation at LC2024 too. Let's hope the newly expanded sales team can make something out of this interest, and next months outlook is back to expectations.

[bamboo2] 30/5/2024 19:06

GRAIL is toast in the UK. It's expensive, [$900+] innacurate and unhelpful to the cause of liquid biopsy as a worthwhile endeavour.

=========================

NHSE will not extend high-profile cancer test pilot

By Ben Clover30 May 2024

NHS England has decided not to extend the ongoing pilot of a high-profile emerging cancer screening technology, casting further doubt on its target to improve early detection.

=========================

Thankfully common-sense has won the day. Grail's [Illumina] test was a poor performer, and relied on spotting later stage cancers. The whole point of Liquid biopsy HAS to be detection of a wide range of different cancers at stage 0 or 1.

Daniel Kim is successfully experimenting using ONT kit and RNA sequencing to find the stage 0/1 cancers.

[luzley] 28/5/2024 11:54

Confident directors here spent half a million pounds on shares in March.

[bamboo2] 28/5/2024 06:48

INNOVATIVE HOSPITAL GENOMIC SURVEILLANCE SYSTEM DETECTS EARLY OUTBREAK OF SERIOUS GUT INFECTION
21 May 2024
MICROBIAL GENOMICS



A team of researchers, including from the Institute of Environmental Science and Research (ESR) and Awanui Labs Wellington, have successfully implemented a Nanopore genomic surveillance system that enabled the early detection and control of a Clostridioides difficile (C. difficile) infection outbreak in a ward of a Wellington-based hospital. The open access findings, described in the journal Infection Control & Hospital Epidemiology, highlight several novel aspects of this approach that could significantly impact future clinical practices.

By prospectively using genomic sequencing, the team was able to identify and manage the C. difficile outbreak at a relatively early stage, demonstrating the potential for such methods to improve patient outcomes and reduce the spread of infections, ultimately making the hospital a safer place for patients. C difficile is a serious bacterial infection of the colon and intestines, which mostly affects people in hospitals.

[bdbd11] 24/5/2024 09:51

Disappointing price action given the good progress at the company. I note INOV are still selling down their holding (you can't blame them as they are using the cash to buy back shares at an excess of 50% nav discount - so they are effectively arbitraging) and there must be other large holders selling in to any strength. Time will tell.

[bamboo2] 24/5/2024 06:58

Oxford Nanopore Technologies Eyes TB Test as First In-House-Developed Diagnostic Test

May 23, 2024 | Huanjia Zhang

Please use link for whole article.



NEW YORK – Oxford Nanopore Technologies has been working on a tuberculosis drug resistance sequencing assay that it hopes will become its first in vitro diagnostic test developed in house.

Dubbed Ampore-TB, the assay will enable TB drug resistance profiling directly ̴3;from sputum samples in about six hours using the GridIon platform and an automated analysis pipeline supported by Epi2me, Oxford Nanopore’s cloud-based bioinformatics platform.

An Oxford Nanopore spokesperson told GenomeWeb that Ampore-TB is currently undergoing internal validation and is slated to be released globally as a research-use-only product later this year. The company plans to obtain regulatory approval for the test under the European Union’s In Vitro Diagnostic Regulation and from the US Food and Drug Administration but did not disclose a timeline.

The GridIon platform will meet the ISO 13485 standard in 2025, the spokesperson also noted, but that instrument will not be specific to TB testing and will only be available to specified partners.

According to Emma Stanton, senior VP of clinical at Oxford Nanopore, a major reason for the company to select Ampore-TB as its first prospective IVD test is "a very clear call to action" from the World Health Organization, which published a new guideline in March recommending the use of targeted next-generation sequencing for the diagnosis of drug-resistant TB.

The guideline specifically highlighted Oxford Nanopore’s Ampore-TB, along with the Deeplex Myc-TB test from Genoscreen in France and the Tbseq assay from Hangzhou ShengTing Medical Technology in China.

Oxford Nanopore has yet to disclose Ampore-TB’s technical specs. Stanton declined to comment on the final format of the assay, citing the early stage of its development.

According to the WHO’s guideline, Ampore-TB, which analyzes sputum samples, is a targeted NGS test developed for the simultaneous identification of mycobacterial species and the detection of mycobacterium tuberculosis (MTBC) complex genetic variants that have been linked to antimicrobial resistance. The guideline noted that Ampore-TB has met the performance criteria to profile resistance to rifampicin, isoniazid, fluoroquinolones, linezolid, amikacin, and streptomycin.

The assay sequences 27 amplicons, including 24 drug resistance targets, a genotyping target, a non-tuberculous mycobacteria identification target (hsp65), and an internal control, using the Oxford Nanopore GridIon device.

Additionally, the guideline noted that the Ampore-TB workflow includes pre-installed analysis software that can automatically generate a report of the test results.

Stanton said Ampore-TB is being developed by Oxford Nanopore internally, with some IP licensed from the UK's Quadram Institute, which the company has been collaborating with to develop the workflow. Once the test is ready, Oxford Nanopore plans to leverage its existing partnership with French in vitro diagnostics firm BioMérieux to help roll it out globally, tapping into the partner's logistics network.

"[BioMérieux’s] role is in helping us to commercialize and distribute the test, they are not developing the test," said Stanton. "Essentially, we will give them the fully developed test, and they will be responsible for distributing it."

"After a year-long partnership with Oxford Nanopore, significant progress has been made towards developing a research use only (RUO) sequencing product for detecting drug resistance in tuberculosis," Charles Cooper, executive VP and chief medical officer of BioMérieux, wrote in an email. "This achievement results from an excellent collaboration between the teams involved. It marks an important milestone in the development of an in vitro diagnostic (IVD) test."

While Cooper’s statement appears to suggest BioMérieux is involved in the development of Ampore-TB, an Oxford Nanopore spokesperson confirmed that the test is completely developed in house by the company. The spokesperson also said BioMérieux is "sharing their indispensable experience on infectious disease diagnostics" with Oxford Nanopore.

Stanton said Oxford Nanopore will have to get regulatory approval from each of the countries it plans to sell Ampore-TB in. The goal is to launch the test in waves, she said, and her team has already begun conversations with regulatory authorities of those countries where the test will first become available.

She did not disclose the names of those countries and did not comment on Oxford Nanopore's plans for regulatory approvals in low- and middle-income countries, where TB testing is in highest demand.

Ampore-TB is not the only sequencing-based TB test highlighted by the WHO. The TBseq test from China’s Hangzhou ShengTing Medical Technology, for instance, also uses the Oxford Nanopore MinIon or GridIon platform. Meanwhile, Genoscreen’s Deeplex Myc-TB can be performed using the Nextera XT and DNA lex library preparation kits and the Illumina iSeq 100, MiniSeq, MiSeq, or NextSeq sequencers, according to the guidelines.

Besides the advantages of nanopore sequencing forTB testing, such as its fast turnaround time and accessibility, the WHO guideline also pointed out some "feasibility challenges" for the technology, including library preparation being "quite complex" and "the need for improved computer analysis and storage capacity."

Beyond targeted NGS, WHO’s guideline also highlighted various other molecular technologies for rapid TB diagnosis and resistance detection, including moderate-complexity automated nucleic acid amplification technologies (NAATs) for the detection of TB and resistance to rifampicin and isoniazid, lateral flow antigen detection tests, low-complexity automated NAATs for the detection of resistance to isoniazid and second-line anti-TB agents, and line-probe assays.

The development of Ampore-TB is spearheaded by Oxford Nanopore Diagnostics, a subsidiary of Oxford Nanopore that was established in 2022 but has largely remained silent since then.

"We haven't spoken about [OND] a lot in the public domain," said Stanton, who heads the subsidiary. While the creation of OND was "necessary for many legal, contractual, and regulatory requirements," she said, her team is "deliberately embedded across in the parent organization" and works closely with the rest of company.

According to Stanton, the OND team includes people working in regulatory affairs and quality assurance. It also has employees with "domain expertise" across various clinical areas, as well as "other people who [have] experience from our competitors in taking sequencing platforms into clinical markets," she added.

Beyond its in-house development efforts, Stanton said an integral part of Oxford Nanopore’s clinical strategy is to forge partnerships with other institutions and companies. Although Ampore-TB is on track to become the company’s first own IVD product, infectious disease is "the smallest target addressable market" for the firm, she said, adding that the company is also eyeing other disease areas such as oncology, transplant diagnostics, as well as rare diseases and other genetic disorders.

Stanton highlighted a series of clinical partnerships the firm has already forged, such as an agreement with Day Zero Diagnostics to develop a diagnostic solution for sepsis, collaborations with Hungarian firm Omixon and Dutch company GenDx to develop HLA transplant diagnostic tests, and a deal with Swiss manufacturer 4bases to develop tests for BRCA1 and BRCA2 breast and ovarian cancer susceptibility genes.

At its annual user meeting in London this week, Oxford Nanopore is holding a dedicated 'Clinical and Biopharma Day' for the first time that is distinct from the main event, signaling the company’s increasing focus on clinical and applied markets

Still, with Ampore-TB’s IVD timeline unclear, it appears that Oxford Nanopore has a way to go to become a diagnostic test manufacturer.

"Whilst we are on a path to have diagnostics, this is really about showcasing and sharing where we are [with the technology]," Stanton said. "It's a Clinical and Biopharma Day, not a Diagnostics Day, quite deliberately."